# Study of Antithrombotic Treatment After IntraCerebral Haemorrhage

Study · id `cardio:ct-nct03186729` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03186729](<https://clinicaltrials.gov/study/NCT03186729>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03186729

Browse, organ or system: Heart; Brain  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 134 participants.

## Technical summary

Registry record NCT03186729. Randomized; single masking; primary purpose prevention. Start 2018-07-01 (actual); primary completion 2024-08-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 134 participants (enrolled count; ClinicalTrials.gov record NCT03186729, source copy `cardio:ctgov-nct03186729-2025-02-12`, retrieved 2026-10-26)
- Started: 2018-07-01 (actual) (ClinicalTrials.gov record NCT03186729, source copy `cardio:ctgov-nct03186729-2025-02-12`, retrieved 2026-10-26)
- Primary completion: 2024-08-31 (actual) (ClinicalTrials.gov record NCT03186729, source copy `cardio:ctgov-nct03186729-2025-02-12`, retrieved 2026-10-26)
- Completion: 2024-08-31 (actual) (ClinicalTrials.gov record NCT03186729, source copy `cardio:ctgov-nct03186729-2025-02-12`, retrieved 2026-10-26)
- Countries: Denmark; Norway; Sweden (ClinicalTrials.gov record NCT03186729, source copy `cardio:ctgov-nct03186729-2025-02-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03186729-2025-02-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of Antithrombotic Treatment After IntraCerebral Haemorrhage
- Acronym: STATICH
- Condition: Cerebral Hemorrhage
- Condition: Intracranial Hemorrhages
- Condition: Atrial Fibrillation
- Condition: Anticoagulant-Induced Bleeding
- Condition: Secondary Prevention
- Intervention (Drug): Antithrombotic Agent
- Lead sponsor: Oslo University Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Bleeding in the brain (intracerebral hemorrhage) (`cardio:intracerebral-hemorrhage`)
- Registry lists this organization as the lead sponsor: Oslo University Hospital (`cardio:org-oslo-university-hospital`)

## Provenance

Content hash: 5fae05cd0022c9ae9e0f004ea469fb93aeae0a575cc3f24a97a5cf45307cd20b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
